Izaskun Ceberio

Av. De Las Universidades 24, 
Bilbao, PV, ES 
Av. De Las Universidades 24, 
Bilbao, PV, ES 

Overview

Izaskun Ceberio practices practicing medicine in Bilbao, Spain.

Their clinical expertise encompasses Graft Versus Host Disease (GvHD), Follicular Lymphoma, Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Bone Marrow Transplant.

They are actively involved in clinical research, co-authoring 9 peer reviewed articles and participating in 2 clinical trials.

Locations

Av. De Las Universidades 24, Bilbao, PV 48007, Spain
Other Locations
San Sebastian, PV 20014, Spain
New York City, NY

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non Candidates to ASCT
Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non Candidates to ASCT
Enrollment Status: Completed
Publish Date: October 10, 2024
Intervention Type: Drug
Study Drugs: Ibrutinib, Rituximab, Gemcitabine, Oxaliplatin, Dexamethasone
Study Phase: Phase 2
A Phase Ib/II Trial of Combined SGN-35 (BrentuximabVedotin) Therapy With Cyclophosphamide, Procarbazine, Prednisone, Etoposide and Mitoxantrone (BrEPEM) for Older Patients With Untreated Hodgkin Lymphoma (HL)
A Phase Ib/II Trial of Combined SGN-35 (BrentuximabVedotin) Therapy With Cyclophosphamide, Procarbazine, Prednisone, Etoposide and Mitoxantrone (BrEPEM) for Older Patients With Untreated Hodgkin Lymphoma (HL)
Enrollment Status: Unknown
Publish Date: February 26, 2024
Intervention Type: Drug
Study Drugs: Brentuximab, Cyclophosphamide, Procarbazine, Prednisone, Etoposide, Mitoxantrone
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

9 Total Publications

Cognitive Functioning in Adults with Phenylketonuria in a Cohort of Spanish Patients.
Cognitive Functioning in Adults with Phenylketonuria in a Cohort of Spanish Patients.
Journal: Behavioural neurology
Published: June 28, 2022

Frequently Asked Questions about Izaskun Ceberio

Is Izaskun Ceberio a top-rated expert for Graft Versus Host Disease (GvHD)?

MediFind is an objective health platform that identifies experts based on real-world data. Izaskun Ceberio is classified as an Experienced expert for Graft Versus Host Disease (GvHD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Izaskun Ceberio participate in research or clinical trials?

Yes. Izaskun Ceberio has published 9 articles and abstracts on conditions like Graft Versus Host Disease (GvHD). You can view a list of Izaskun Ceberio's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ceberio's expertise for a condition
ConditionClose
        View All 9 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile